{
    "ticker": "BBLB",
    "name": "Bluebird Bio, Inc.",
    "description": "Bluebird Bio, Inc. is a biotechnology company focused on developing innovative gene therapies for serious genetic diseases and cancer. Founded in 1992, Bluebird Bio aims to transform the treatment landscape for patients with rare genetic disorders, including beta-thalassemia, sickle cell disease, and certain inherited neurological diseases. The company utilizes its proprietary gene-editing technology to address the underlying causes of these diseases at the genetic level, offering hope for long-term, potentially curative treatments. Bluebird Bio's lead product candidates include LentiGlobin for beta-thalassemia and sickle cell disease, which are currently in various stages of clinical trials. The company also has a robust pipeline of investigational therapies targeting different genetic conditions and malignancies, reflecting its commitment to advancing the field of gene therapy. Bluebird Bio is headquartered in Cambridge, Massachusetts, and collaborates with leading academic institutions and research organizations to drive innovation and bring transformative therapies to patients. The company's mission is to provide patients with access to potentially life-saving treatments, emphasizing the importance of patient-centric care and community engagement in the development of its therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "1992",
    "website": "https://www.bluebirdbio.com",
    "ceo": "Andrew Obenshain",
    "social_media": {
        "twitter": "https://twitter.com/bluebirdbio",
        "linkedin": "https://www.linkedin.com/company/bluebird-bio"
    },
    "investor_relations": "https://investors.bluebirdbio.com",
    "key_executives": [
        {
            "name": "Andrew Obenshain",
            "position": "CEO"
        },
        {
            "name": "Nick Leschly",
            "position": "Former CEO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "LentiGlobin",
                "bb1111"
            ]
        }
    ],
    "seo": {
        "meta_title": "Bluebird Bio, Inc. | Gene Therapy for Genetic Diseases and Cancer",
        "meta_description": "Explore Bluebird Bio, Inc., a leader in gene therapy focused on treating genetic diseases and cancer through innovative technologies.",
        "keywords": [
            "Bluebird Bio",
            "Gene Therapy",
            "Beta-thalassemia",
            "Sickle Cell Disease",
            "Genetic Disorders"
        ]
    },
    "faq": [
        {
            "question": "What is Bluebird Bio known for?",
            "answer": "Bluebird Bio is known for its development of gene therapies for serious genetic diseases and cancer."
        },
        {
            "question": "Who is the CEO of Bluebird Bio?",
            "answer": "Andrew Obenshain is the CEO of Bluebird Bio, Inc."
        },
        {
            "question": "Where is Bluebird Bio headquartered?",
            "answer": "Bluebird Bio is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Bluebird Bio's main products?",
            "answer": "Bluebird Bio's main products include LentiGlobin and other investigational gene therapies."
        },
        {
            "question": "When was Bluebird Bio founded?",
            "answer": "Bluebird Bio was founded in 1992."
        }
    ],
    "competitors": [
        "EDIT",
        "CRSP",
        "NTLA",
        "SGEN"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "VRTX"
    ]
}